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FLAP inhibitorPrevious studies revealed the presence of LTC4 synthase in paraventricular vasopressinergic neurons,
suggesting a role for leukotrienes (LTs) in certain neuroendocrine system functions. Our aim was to study
the effect of an inhibitor of LT synthesis in the release of arginine vasopressin (AVP) following an osmotic
stimulus in rats. Male Wistar rats received an intra-cerebroventricular injection of 2 μl of the LT synthesis in-
hibitor MK-886 (1, 2, or 4 μg/kg), or vehicle (DMSO 5%), 1 h before an intraperitoneal injection of hypertonic
saline (NaCl 2 M) or isotonic saline (NaCl 0.01 M) in a volume corresponding to 1% of body weight. Thirty
minutes after the osmotic stimulus, the animals were decapitated and blood was collected for determining
hematocrit, plasma osmolality and plasma AVP levels. As expected, the injection of hypertonic saline signif-
icantly increased (Pb0.05) the hematocrit, plasma osmolality and plasma AVP levels. While inhibiting LT syn-
thesis by central administration of MK-886 did not cause any additional increase in hematocrit or osmolality,
plasma AVP levels were augmented (Pb0.05). We conclude that central leukotrienes may have a modulatory
role in AVP secretion following an osmotic stimulus, this deserving future studies.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Vasopressin (AVP), also known as antidiuretic hormone, is a
nonapeptide synthetized by magnocellular neurons, primarily located
in the supraoptic (SON) and paraventricular (PVN) nuclei of the hy-
pothalamus, but also found in the circularis nucleus situated between
the SON and PVN. The axons of these neurons project to the
neurohyophysis, where the hormone is stored and, following ade-
quate stimuli, secreted into the circulation [1,2].
The most important stimulus for AVP secretion is hyperosmolality
[3], but other non-osmotic stimuli, viz. hypovolemia, hypotension,
hypoxia, hypercapnia, pain, nausea, and fever can also lead to an in-
crease in plasma hormone levels [2,4–6]. AVP release is also augment-
ed by endotoxins, prostaglandins and interleukin-1 [7–9]. Recently,
we reported an increase in AVP secretion occurring during the early
phase of sepsis that correlated with the production of leukotrienes
in the central nervous system [10].e no conﬂicts of interest.
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tral nervous system [11,12], being derived from arachidonic acid via the
5-lipoxygenase (5-LO) pathway. The enzyme 5-LO, in conjunction with
its helper protein 5-LO-activating protein (FLAP), catalyzes the reaction
that transforms arachidonic acid into the unstable intermediate
5-hydroxyperoxy-6,8,11,14-eicosatetranoic acid (5-HPETE), which is
then rapidly converted to LTA4. This is also an unstable intermediate
that can be either hydrolyzed to form LTB4, or conjugatedwith glutathi-
one by LTC4 synthase to produce the cysteinylleukotrienes (cys-LTs)
LTC4, LTD4 and LTE4 [13,14]. 5-LO and FLAP are found in neurons of sev-
eral brain regions, including the hippocampus, cerebellum, thalamus,
hypothalamus, and brain stem [15]. LTB4 is produced rather uniformly
throughout the entire rat brain, with the highest concentrations of LTC4
being detected in the hypothalamus and the median eminence [16,17].
LTC4 synthase was shown to be selectively localized in neurons of
the PVN and SONof the hypothalamus, aswell as in the suprachiasmatic
and retrochiasmatic nuclei in mice. Such LTC4 synthase localization
seems to be speciﬁc for vasopressinergic neurons, since oxytocinergic
neurons did not show LTC4 synthase immunoreactivity, suggesting
that the enzyme is particularly involved in AVP functions within the
neuroendocrine system [18].
While an osmotic stimulus is a typical physiological condition for
AVP secretion, sepsis conditions also lead to a major increase in AVP se-
cretion [7–9], but in a pathological background, not driven by an osmot-
ic stimulus. Hence, we askedwhether the relationship between LTs and
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during hyperosmolality, and hitherto we investigated the effects of a
centrally administered LT synthesis blocker on AVP release during
hyperosmolality in rats.
2. Material and methods
2.1. Animals
Wistar male rats (200–300 g) obtained from the Animal Care Fa-
cility of Universidade de São Paulo (USP), Campus Ribeirão Preto
were used in the present experiments. The rats were housed in a con-
trolled temperature (25±1°C) and photoperiod (12:12 h night:day
cycle) conditions, with food (Nuvilab CR-1, NUVITAL) and water
available ad libitum. All experimental protocols were performed
according to the guidelines of the Ethics Committee of USP (CEUA)-
Campus Ribeirão Preto.
2.2. Drug
The 5-lipoxygenase-activating protein (FLAP) and LTC4 synthase
inhibitor MK-886, chemically known as 3-[1-(p-chlorobenzyl)-5-
(isopropyl)-3-tert-butylthioindol-2-yl]-2, 2-dimethylpropanoic acid
(Merck), was dissolved in 5% dimethylsulfoxide (DMSO).
2.3. Cannulation procedure
The animals were anesthetized with 2, 2, 2-tribromoethanol
(Across Organics, 250 mg/kg i.p.) and ﬁxed in a stereotaxic frame. A
stainless guide cannula (0.7 mm outer diameter) was introduced
into the right lateral ventricle (coordinates: A: −0.8 mm, L:
1.4 mm, D: 3.2–3.7 mm). The cannula was attached to the bone via
stainless steel screws and acrylic cement. A tight-ﬁtting style was
kept inside the guide cannula to prevent occlusion. After surgery,
the animals were treated with 100,000 units of benzyl–penicillin
and allowed to recover for 5–7 days.
2.4. Experimental protocol
Intracerebroventricular (i.c.v.) injections were performed using a
10 μl Hamilton syringe and a dental injection needle (200 μm outer
diameter; Mizzy, Brazil). The volume of each injection was 2 μl for
all protocols. Injections were given over a period of 1 min, and an ad-
ditional minute was allowed to elapse before the injection needle was
withdrawn from the guide cannula, so as to avoid reﬂux. The animals
received an i.c.v. injection of MK-886 (1, 2, or 4 μg/kg of body weight)
dissolved in 5% DMSO, or an injection of this vehicle. One hour later,
an osmotic stimulus consisting of an intraperitoneal (i.p.) injection
of hypertonic saline (2 M NaCl) in a volume corresponding to10%
body weight was given. An i.p. injection of isotonic saline (0.01 M
NaCl) served as control for the osmotic stimulus. Thirty minutes
after the osmotic stimulus, the animals were decapitated and blood
was collected for hematocrit, plasma osmolality and plasma AVP
measurement.
2.5. Determination of hematocrit and plasma osmolality
Hematocrit was measured by centrifugation and plasma osmolal-
ity by freezing-point depression (Precision System, INC., USA).
2.6. Radioimmunoassay for vasopressin
A radioimmunoassay (RIA) for AVP was performed as previously
described [19]. Brieﬂy, plasma samples (1.0 ml) were extracted
using the acetone/petroleum ether method, lyophilized and stored
at −70 °C until analysis. Standard reagents and incubation protocolswere used for the peptide assays. AVP measurements were done
using a commercial antiserum (Peninsula Laboratories) at a ﬁnal dilu-
tion of 1:40,000 in a phosphate buffer (0.062 M Na2HPO4, pH 7.5,
containing 0.013 M Na2EDTA and 0.5% BSA). The antiserum is speciﬁc
for AVP and essentially shows no cross-reactivity with other known
peptides. For peptide labeling, 125I was purchased from a commercial
supplier (Amersham). A non-equilibrium assay was used with an in-
cubation volume of 500 μl and an incubation time of 4 days at 4 °C.
Bound hormone was separated from unbound by a secondary anti-
body produced in the laboratory where the RIA was performed. The
minimum detection limit was 0.9 pg/ml and the coefﬁcients of
inter- and intra-assay variation were 11% and 7%, respectively.
2.7. Data analysis
The data are reported as mean±S.E.M. Analysis of variance
(ANOVA) and a post hoc Student–Newman–Keuls (SNK) test were
used to reveal statistical differences among treatment and stimulus.
For further analyses, Student's t-tests were used to directly compare
groups. Values of Pb0.05 were considered statistically signiﬁcant.
Raw RIA data were logit transformed before testing.
3. Results
Following the intraperitoneal injection of hypertonic saline, an in-
crease was seen, as expected, in both osmolality (321±4 vs. 287±2
control, Pb0.001) and AVP plasma levels (12.7±1.9 vs 1.3±0.1 con-
trol, Pb0.001), already 30 min after the injection. An increase in the
hematocrit (40±0.7 vs 36±1.5 control, P=0.030) was also noted,
but this being at a lower level than the one necessary to trigger an
AVP release. The i.c.v. injection of 5% DMSO, serving as vehicle to dis-
solve the FLAP and LTC4 synthase inhibitor MK-886, did not affect the
levels of plasma AVP, osmolality, or hematocrit seen in animals
injected with hypertonic or isotonic saline.
An i.c.v. injection of 2 μl of MK-886 given 1 h prior to the injection
of isotonic saline also did not cause any alteration in the hematocrit,
osmolality, or AVP plasma levels. But when this drug was given at
doses of 2.0 or 4.0 μg/kg prior to the osmotic stimulus we noted a
further signiﬁcant increase in AVP plasma levels (F(3,66)=31,62,
Pb0.001) while hematocrit and osmolality were not affected (Fig. 1).
4. Discussion
The present study was designed to examine whether LTs may
modulate the osmotic stimulus-induced AVP release. We noted that
the central injection of the LT synthesis blocker MK-886 further aug-
mented the plasma AVP levels beyond those normally seen after in-
traperitoneal injection of hypertonic saline in rats. This leads us to
infer that central leukotriene production may contribute to attenuat-
ing the AVP release that normally occurs in response to an osmotic
stimulus, in the sense of preventing an overshooting of this humoral
response. To our knowledge this is the ﬁrst time that central LTs
could be connected to AVP secretion during such a stimulus.
A neuroendocrine role for LTs was ﬁrst suggested by the
colocalization of gonadotropin-releasing hormone (GnRH) and LTC4 in
neurons of themedian eminence in rats [12]. Subsequent in vitro studies
showed that the release of luteinizinghormone (LH) frompituitary cells
in response to GnRH was partly mediated by LTs, and this response
appeared to be LTC4-speciﬁc, since LTB4 did not alter the release of
luteinizing hormone [12]. Further studies revealed that LTC4 synthase
is selectively localized in the hypothalamic and extrahypothalamic va-
sopressin systems, suggesting the involvement of cys-LTs in neuroen-
docrine system and, especially vasopressinergic neural functions [18].
An increase in plasma osmolality is a strong stimuli for AVP re-
lease [4], and the increase in osmolality seen in our study (more
than the 4%) was considered adequate for triggering AVP secretion.
Fig. 1. Effect of a central administration of the 5-lipoxygenase-activating protein
(FLAP) and LTC4 synthase inhibitor MK-886, or its vehicle (5%DMSO) on hematocrit
(upper panel), plasma osmolality (middle panel) and plasma vasopressin levels
(lower) panel in response to an intraperitoneal injection of hypertonic (2 M NaCl) or
isotonic saline ( 0.01 M NaCl). The number of animals analyzed in each group was 5
to 7. The results are expressed as means±SEM. * Pb0.05 compared to the isotonic sa-
line group. + Pb0.05 compared to the vehicle (5% DMSO) group. § Pb0.05 compared
within the group.
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given an osmotic stimulus, it is further inferred that the additional
increase in AVP levels seen in this situation cannot be attributed to
a change in osmolality. When looking for alternatives we ﬁrst consid-
ered hypovolemia, which is another stimulus for AVP secretion [20].Even though we could see an increase in the hematocrit accompany-
ing the increase in plasma AVP levels, the magnitude of hypovolemia
observed was judged as being too low to explain the increase in AVP
plasma levels seen in our experimental design. Furthermore, MK-886
pretreatment did not affect hematocrit levels, thus indicating that the
enhanced increase in AVP levels in response to hypertonic saline in-
jection was not a consequence of a decrease in volemia.
Although we did not analyze LTC4 synthase content in this study,
we had obtained evidence in a prior study that an i.c.v. injection of
MK-886 reduces the content of this enzyme in the respective brain
regions during a sepsis condition [10]. But interestingly, in this path-
ophysiological condition, the MK-886 injection caused a reduction in
AVP secretion in the early phase of sepsis, whereas in the physiolog-
ical condition of an osmotic stimulus AVP secretion was further en-
hanced. This makes sense, as in a physiological condition, endocrine
responses involved in homeostasis always require a careful balance,
and in this situation leukotrienes would actually prevent an over-
shoot in the AVP release by hypothalamic neurons. In contrast, in
the pathological condition of sepsis, hypotension occurs in combina-
tion with a strong inﬂammatory response, so the organism may use
inﬂammatory mediators, including leukotrienes, in an attempt to
regain control of blood pressure. Further investigating the dual role
of centrally produced leukotrienes in blood pressure control should,
thus, certainly be a goal worthwhile to pursue.
5. Conclusion
The results of this study lead us to conclude that leukotrienes play
a role in AVP secretion induced by an osmotic stimulus in rats. In this
situation they actually seem to attenuate the humoral response, in
contrast to their role seen in sepsis, where they further activate AVP
release. So far we have no deﬁnitive explanation for this differential
AVP response to the i.c.v. MK-886 injection, but we hypothesize
that during sepsis vasopressin secretion is caused by both inﬂamma-
tory mediators and hypotension, which together activate one path-
way, whereas in the hyperosmotic condition, the activation of
vasopressinergic neurons would involve a different pathway. An os-
motic stimulus is typically not associated with a high production of
nitric oxide, cytokines, or leukotrienes, as seen during sepsis condi-
tions. So, while leukotrienes seem to activate vasopressin secretion
during sepsis, these mediators seem to be inhibitory during an osmot-
ic stimulus.
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